ORTEXORTEX News
Tracking HURN? Get live short interest, options flow, and signals on ORTEX.Sign up free →
HU
Earnings PreviewHURN

Truist Raises HURN Target 26% Days Before Q3 Print

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 24 Oct 2026, 04:02

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Truist Securities analyst Tobey Sommer lifted his price target on HURN to $220 from $175 yesterday, keeping his Buy rating intact, and the timing is striking: Huron Consulting Group reports Q3 results on Monday, October 27. The stock has gained 12% over the past week to $195.69, outpacing a median 7.3% rise among its closest peers, and is up 24% over the past month. The Truist move reversed a June cut to $155 from $240, making the new $220 target an aggressive reassertion of conviction just before the print.

The lending market gives no hint of meaningful short pressure. Availability is at 1,115%, meaning shares available to borrow dwarf the existing short position by more than eleven to one. That is the tightest availability has been in 52 weeks, but the absolute level remains extremely loose. Cost to borrow is 0.50%, up 14% on the week, a move that is directionally notable but still negligible in absolute terms. Short interest at 5.3% of free float has drifted down 4.4% over the past week after rising about 29% over the prior month. Options positioning is also relaxed: the put/call ratio of 0.69 is slightly below its 20-day average, implying no unusual demand for downside protection.

The bull case rests on non-discretionary healthcare demand and a managed services business growing at mid-20s segment margins. Truist's raised target aligns with the $202 consensus mean and Barrington Research's standing $207 Outperform target. Bears point to operating cash flow that deteriorated to negative $162 million last quarter, an 8.2% operating margin that missed expectations, and structural headwinds across higher education, including enrollment declines and federal funding uncertainty. EV/EBITDA has expanded to 11.1x over the past 30 days as the stock re-rated, leaving less room for execution stumbles.

Retail attention has picked up sharply, with a Wikipedia page-view z-score of 2.2 against Huron's own 90-day history, the highest reading in the dataset's recent window. That alone is colour rather than a fundamental signal, but it coincides with the insider record: net selling of roughly $4.4 million over the past 90 days, including CEO C. Mark Hussey offloading shares across multiple transactions in late July under a 10b5-1 plan. Director Hugh Sawyer sold 2,000 shares in August outside a plan, a more discretionary signal, though at $308,500 it is small relative to the company's $2.9 billion market cap. On the buy side, BlackRock added 74,753 shares through September and Principal Global Investors added nearly 145,000, suggesting institutional appetite has not dried up. Closest peer EXLS gained 9.7% on the week and CRAI rose 13.3%, confirming the sector tailwind behind HURN's own move rather than a company-specific re-rating.

Monday's print is the first test of whether Huron's revenue-cycle managed services growth can translate into the cash generation that would justify a PE ratio now running near 18.7x, and whether management's 2026 guidance of $1.78 to $1.86 billion in revenue with 14.5% to 15.0% adjusted EBITDA margins still holds after a quarter shaped by federal funding uncertainty in its education segment.

Stocks in this article

See the live data behind this article on ORTEX.

Open HURN on ORTEX →

How this article was generated

Generated
24 Oct 2026, 04:26
Data as of
24 Oct 2026, 04:02
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.